Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer

被引：0
|
作者：
Huang Xiaomei [1 ]
Liu Zaiyi [2 ]
机构：
[1] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China
[2] Guangdong Acad Med Sci, Dept Radiol, Guangdong Prov Peoples Hosp, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
来源：
JAMA ONCOLOGY | 2022年 / 8卷 / 04期
关键词：
D O I：
10.1001/jamaoncol.2021.7997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：645 / 646
页数：1
相关论文
共 50 条
  • [21] Event-free survival by residual cancer burden after neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
    Pusztai, Lajos
    Denkert, Carsten
    O'Shaughnessy, Joyce
    Cortes, Javier
    Dent, Rebecca Alexandra
    McArthur, Heather L.
    Kuemmel, Sherko
    Bergh, Jonas C. S.
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Zhu, Yalin
    Pan, Wilbur
    Tryfonidis, Konstantinos
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Tumor Characteristics and Event-free Survival in Older and Younger Patients with Breast Cancer
    Kodikara, S.
    Deal, A. M.
    Page, A.
    Muss, H.
    Nyrop, K.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 : S192 - S192
  • [23] Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
    Suppan, Christoph
    Posch, Florian
    Mueller, Hannah Deborah
    Mischitz, Nina
    Steiner, Daniel
    Klocker, Eva Valentina
    Setaffy, Lisa
    Bargfrieder, Ute
    Hammer, Robert
    Hauser, Hubert
    Jost, Philipp J.
    Dandachi, Nadia
    Lax, Sigurd
    Balic, Marija
    CANCERS, 2021, 13 (10)
  • [24] Biomarkers of residual disease after neoadjuvant therapy for breast cancer
    Penault-Llorca, Frederique
    Radosevic-Robin, Nina
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 487 - 503
  • [25] Biomarkers of residual disease after neoadjuvant therapy for breast cancer
    Frederique Penault-Llorca
    Nina Radosevic-Robin
    Nature Reviews Clinical Oncology, 2016, 13 : 487 - 503
  • [26] Correlation analysis of Ki67 changes with survival outcomes in breast cancer before and after neoadjuvant therapy based on residual cancer Burden grade
    Ju, Xianli
    Chen, Zhengzhuo
    Yan, Honglin
    Luo, Bin
    Zhao, Fangrui
    Huang, Aoling
    Chen, Xi
    Yuan, Jingping
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263
  • [27] Residual Nodal Burden in Patients Undergoing Neoadjuvant Endocrine Therapy for Breast Cancer
    Kantor, O.
    Wakeman, M.
    Weiss, A.
    Metzger, O.
    Wong, S. M.
    Laws, A.
    Grossmith, S. C.
    Mittendorf, E. A.
    King, T. A.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S14 - S14
  • [28] Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy
    Elder, Erin A.
    Livasy, Chad A.
    Donahue, Erin E.
    Neelands, Brittany
    Patrick, Alicia
    Needham, Mckenzie
    Sarantou, Terry
    Hadzikadic-Gusic, Lejla
    Heeke, Arielle L.
    White, Richard L., Jr.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (13) : 8060 - 8069
  • [29] The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
    Xu, Xin
    Zhao, Wei
    Liu, Cuicui
    Gao, Yongsheng
    Chen, Dawei
    Wu, Meng
    Li, Chao
    Wang, Xinzhao
    Song, Xiang
    Yu, Jinming
    Liu, Zhaoyun
    Yu, Zhiyong
    BMC CANCER, 2024, 24 (01)
  • [30] Residual cancer burden and neoangiogenesis after neoadjuvant chemotherapy in triple-negative breast cancer
    Miyashita, M.
    Sasano, H.
    Tamaki, K.
    Hirakawa, H.
    Ishida, T.
    Ohuchi, N.
    BREAST, 2017, 32 : S100 - S101
12345